The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing WeightWatchers to reboot its drug strategy.

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar deal with Hims & Hers Health (NYSE:HIMS) that gave the telehealth firm direct access to the company's blockbuster GLP-1 therapy.